Equitable Trust Co. Makes New $326,000 Investment in Humana Inc. $HUM

Key Points

• Equitable Trust Co. has invested approximately $326,000 in a new position of 1,333 shares of Humana Inc. during the second quarter.
• Overall, 92.38% of Humana's stock is currently owned by institutional investors, indicating strong institutional interest.
• Humana recently reported earnings of $6.27 per share for the last quarter, falling short of analysts' expectations, though revenue grew by 9.6% year-over-year.

Equitable Trust Co. bought a new position in shares of Humana Inc. (NYSE:HUM - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,333 shares of the insurance provider's stock, valued at approximately $326,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. NorthRock Partners LLC lifted its stake in Humana by 199.6% during the second quarter. NorthRock Partners LLC now owns 2,394 shares of the insurance provider's stock worth $585,000 after purchasing an additional 1,595 shares during the last quarter. Atria Wealth Solutions Inc. lifted its stake in Humana by 10.3% during the second quarter. Atria Wealth Solutions Inc. now owns 955 shares of the insurance provider's stock worth $234,000 after purchasing an additional 89 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in Humana by 112.3% during the second quarter. Sequoia Financial Advisors LLC now owns 3,790 shares of the insurance provider's stock worth $927,000 after purchasing an additional 2,005 shares during the last quarter. Pzena Investment Management LLC lifted its stake in Humana by 6.5% during the second quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider's stock worth $996,664,000 after purchasing an additional 247,744 shares during the last quarter. Finally, Leith Wheeler Investment Counsel Ltd. lifted its stake in Humana by 661.7% during the second quarter. Leith Wheeler Investment Counsel Ltd. now owns 1,038,703 shares of the insurance provider's stock worth $253,942,000 after purchasing an additional 902,340 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

NYSE HUM opened at $262.29 on Thursday. The company has a market capitalization of $31.55 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 1.53 and a beta of 0.42. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $315.35. The stock has a fifty day simple moving average of $280.15 and a 200 day simple moving average of $258.14. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business's revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Friday, September 26th. Humana's dividend payout ratio (DPR) is presently 27.17%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on HUM shares. Guggenheim restated a "buy" rating on shares of Humana in a research note on Friday, October 3rd. Bank of America upped their price target on shares of Humana from $280.00 to $300.00 and gave the stock a "neutral" rating in a report on Friday, October 10th. Wells Fargo & Company upped their price target on shares of Humana from $344.00 to $347.00 and gave the stock an "overweight" rating in a report on Tuesday, October 7th. Mizuho upped their price target on shares of Humana from $300.00 to $345.00 and gave the stock an "outperform" rating in a report on Thursday, October 9th. Finally, Wall Street Zen downgraded shares of Humana from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Humana currently has a consensus rating of "Hold" and an average target price of $297.58.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.